GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aegerion Pharmaceuticals Inc (NAS:AEGR) » Definitions » Quick Ratio

Aegerion Pharmaceuticals (Aegerion Pharmaceuticals) Quick Ratio : 0.67 (As of Sep. 2016)


View and export this data going back to 2010. Start your Free Trial

What is Aegerion Pharmaceuticals Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Aegerion Pharmaceuticals's quick ratio for the quarter that ended in Sep. 2016 was 0.67.

Aegerion Pharmaceuticals has a quick ratio of 0.67. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Aegerion Pharmaceuticals's Quick Ratio or its related term are showing as below:

AEGR's Quick Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.485
* Ranked among companies with meaningful Quick Ratio only.

Aegerion Pharmaceuticals Quick Ratio Historical Data

The historical data trend for Aegerion Pharmaceuticals's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aegerion Pharmaceuticals Quick Ratio Chart

Aegerion Pharmaceuticals Annual Data
Trend Dec05 Dec06 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.88 4.95 5.59 9.99 1.35

Aegerion Pharmaceuticals Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.68 1.35 0.83 0.77 0.67

Competitive Comparison of Aegerion Pharmaceuticals's Quick Ratio

For the Biotechnology subindustry, Aegerion Pharmaceuticals's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aegerion Pharmaceuticals's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aegerion Pharmaceuticals's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Aegerion Pharmaceuticals's Quick Ratio falls into.



Aegerion Pharmaceuticals Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Aegerion Pharmaceuticals's Quick Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Quick Ratio (A: Dec. 2015 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(175.938-58.706)/86.887
=1.35

Aegerion Pharmaceuticals's Quick Ratio for the quarter that ended in Sep. 2016 is calculated as

Quick Ratio (Q: Sep. 2016 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(120.778-41.517)/118.787
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aegerion Pharmaceuticals  (NAS:AEGR) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Aegerion Pharmaceuticals Quick Ratio Related Terms

Thank you for viewing the detailed overview of Aegerion Pharmaceuticals's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aegerion Pharmaceuticals (Aegerion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada. The Company also sells lomitapide, on a named patient basis, in Brazil and in a limited number of other countries outside the U.S. and the EU where such sales are authorized based on the U.S. or the EU approval. The Company also launched JUXTAPID in the U.S. The Company relies on a contract manufacturer to produce drug substance for lomitapide and another contract manufacturer for drug product for its clinical trials and for commercial supplies. It distributes JUXTAPID through a specialty pharmacy that distributes JUXTAPID directly to patients and, under limited circumstances, to other purchasers. The lomitapide patent portfolio consists of five issued U.S. patents and issued patents in Europe, Canada, Israel, Australia, New Zealand and Japan and pending applications in the U.S., Australia, Japan, Canada, India and South Korea, all of which have been licensed in a specific field. The Company competes with Regeneron Pharmaceuticals, Inc., in collaboration with Sanofi, Roche Holding AG, Pfizer Inc., Amgen Inc., and Alnylam Pharmaceuticals, Inc. The Company's operations are subject to federal, state and local level, the EU and other countries extensively regulations.
Executives
Anne Vanlent director C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Benjamin Harshbarger officer: General Counsel and Secretary ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Sandford D Smith director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Kevin Kotler 10 percent owner C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc 10 percent owner 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd 10 percent owner C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Gregory D Perry other: See Remarks C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Gotto Antonio M Jr Md D Phil director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Jorge Md Plutzky director C/O VIVUS, INC. 1172 CASTRO STREET MOUNTAIN VIEW CA 94040
Paul Thomas director ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Sol J Barer director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Mary T Szela director, officer: Chief Executive Officer 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
John J Orloff officer: EVP, Research and Development C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Martha J. Carter officer: See Remarks C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Eric Curtis officer: President, U.S. Commercial ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142

Aegerion Pharmaceuticals (Aegerion Pharmaceuticals) Headlines

From GuruFocus